Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

2.

Do we still need a malaria vaccine?

Greenwood B, Targett G.

Parasite Immunol. 2009 Sep;31(9):582-6. doi: 10.1111/j.1365-3024.2009.01140.x. Review.

3.

MSP-1p42-specific antibodies affect growth and development of intra-erythrocytic parasites of Plasmodium falciparum.

Bergmann-Leitner ES, Duncan EH, Angov E.

Malar J. 2009 Aug 3;8:183. doi: 10.1186/1475-2875-8-183.

4.

Temporal stability of naturally acquired immunity to Merozoite Surface Protein-1 in Kenyan adults.

Dent AE, Chelimo K, Sumba PO, Spring MD, Crabb BS, Moormann AM, Tisch DJ, Kazura JW.

Malar J. 2009 Jul 16;8:162. doi: 10.1186/1475-2875-8-162.

5.

Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial.

Lyke KE, Daou M, Diarra I, Kone A, Kouriba B, Thera MA, Dutta S, Lanar DE, Heppner DG Jr, Doumbo OK, Plowe CV, Sztein MB.

Vaccine. 2009 Mar 26;27(15):2171-6. doi: 10.1016/j.vaccine.2009.01.097. Epub 2009 Jan 31.

6.

Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya.

Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, Tucker K, Waitumbi JN, Diggs C, Wittes J, Malkin E, Leach A, Soisson LA, Milman JB, Otieno L, Holland CA, Polhemus M, Remich SA, Ockenhouse CF, Cohen J, Ballou WR, Martin SK, Angov E, Stewart VA, Lyon JA, Heppner DG, Withers MR; MSP-1 Malaria Vaccine Working Group.

PLoS One. 2009;4(3):e4708. doi: 10.1371/journal.pone.0004708. Epub 2009 Mar 5.

7.

Association of early interferon-gamma production with immunity to clinical malaria: a longitudinal study among Papua New Guinean children.

D'Ombrain MC, Robinson LJ, Stanisic DI, Taraika J, Bernard N, Michon P, Mueller I, Schofield L.

Clin Infect Dis. 2008 Dec 1;47(11):1380-7. doi: 10.1086/592971.

PMID:
18947328
8.

Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses.

Lyon JA, Angov E, Fay MP, Sullivan JS, Girourd AS, Robinson SJ, Bergmann-Leitner ES, Duncan EH, Darko CA, Collins WE, Long CA, Barnwell JW.

PLoS One. 2008 Jul 30;3(7):e2830. doi: 10.1371/journal.pone.0002830.

9.

Fine specificity of neonatal lymphocytes to an abundant malaria blood-stage antigen: epitope mapping of Plasmodium falciparum MSP1(33).

Malhotra I, Wamachi AN, Mungai PL, Mzungu E, Koech D, Muchiri E, Moormann AM, King CL.

J Immunol. 2008 Mar 1;180(5):3383-90.

10.

Ex vivo cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum merozoite surface protein-1 in vaccinated volunteers.

Huaman MC, Martin LB, Malkin E, Narum DL, Miller LH, Mahanty S, Long CA.

J Immunol. 2008 Feb 1;180(3):1451-61.

11.

Pattern of malaria-specific T-cell responses in a cohort of Ugandan children.

Ssewanyana I, Pietras C, Baker CA, Nghania F, Jones NG, Rosenthal PJ, Dorsey G, Cao H.

J Trop Pediatr. 2008 Feb;54(1):6-13. Epub 2007 Nov 4.

PMID:
17984125
12.

A polymerase chain reaction/ligase detection reaction fluorescent microsphere assay to determine Plasmodium falciparum MSP-119 haplotypes.

Dent AE, Yohn CT, Zimmerman PA, Vulule J, Kazura JW, Moormann AM.

Am J Trop Med Hyg. 2007 Aug;77(2):250-5.

13.

Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali.

Takala SL, Coulibaly D, Thera MA, Dicko A, Smith DL, Guindo AB, Kone AK, Traore K, Ouattara A, Djimde AA, Sehdev PS, Lyke KE, Diallo DA, Doumbo OK, Plowe CV.

PLoS Med. 2007 Mar;4(3):e93.

14.
15.

Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya.

Stoute JA, Gombe J, Withers MR, Siangla J, McKinney D, Onyango M, Cummings JF, Milman J, Tucker K, Soisson L, Stewart VA, Lyon JA, Angov E, Leach A, Cohen J, Kester KE, Ockenhouse CF, Holland CA, Diggs CL, Wittes J, Heppner DG Jr; MSP-1 Malaria Vaccine Working Group.

Vaccine. 2007 Jan 2;25(1):176-84. Epub 2005 Dec 7.

PMID:
16388879
16.

Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine.

Ockenhouse CF, Angov E, Kester KE, Diggs C, Soisson L, Cummings JF, Stewart AV, Palmer DR, Mahajan B, Krzych U, Tornieporth N, Delchambre M, Vanhandenhove M, Ofori-Anyinam O, Cohen J, Lyon JA, Heppner DG; MSP-1 Working Group.

Vaccine. 2006 Apr 5;24(15):3009-17. Epub 2005 Nov 28.

PMID:
16356603
17.

The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites.

Darko CA, Angov E, Collins WE, Bergmann-Leitner ES, Girouard AS, Hitt SL, McBride JS, Diggs CL, Holder AA, Long CA, Barnwell JW, Lyon JA.

Infect Immun. 2005 Jan;73(1):287-97.

19.

Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA class I loci.

Cao K, Moormann AM, Lyke KE, Masaberg C, Sumba OP, Doumbo OK, Koech D, Lancaster A, Nelson M, Meyer D, Single R, Hartzman RJ, Plowe CV, Kazura J, Mann DL, Sztein MB, Thomson G, Fernández-Viña MA.

Tissue Antigens. 2004 Apr;63(4):293-325.

PMID:
15009803
20.

HLA-A and HLA-B in Kenya, Africa: allele frequencies and identification of HLA-B*1567 and HLA-B*4426.

Luo M, Embree J, Ramdahin S, Ndinya-Achola J, Njenga S, Bwayo JB, Pan S, Mao X, Cheang M, Stuart T, Brunham RC, Plummer FA.

Tissue Antigens. 2002 May;59(5):370-80.

PMID:
12144620

Supplemental Content

Support Center